Abstracts Archive - Page 135 of 2607 - ACR Meeting Abstracts

Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…
Abstract Number: 1548 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Miriam Retuerto Guerrero², Judit Font-Urgelles³, Ivette Casafont-Solé³, Adrián Mayo-Juanatey⁴, Juan José Alegre-Sancho⁵, DALIFER FREITES⁶, Cristina Hormigos Martin⁷, Noemí Garrido⁸, GUILLERMO GONZALEZ ARRIBAS⁹, Juan Roberto Miguelez Sanchez¹⁰, Andrea García-Valle¹¹, Marta Ibañez¹², Fernando Lozano Morillo¹³, Ángel García Manzanares¹⁴, Sebastián Sandoval-Moreno¹⁵, Josefina Cortés-Hernández¹⁶, Deseada Palma-Sanchez¹⁷, LETICIA LOJO-OLIVEIRA¹⁸, Evelin Cervantes¹⁹, Paz Collado Ramos²⁰, cristina arciniega Larios²¹, Luis Sala²², Eztizen Labrador-Sánchez²³, Cilia Peralta-Ginés²⁴, Nahia Plaza-Aulestia²⁵, Irati Urionaguena Onaindia²⁶, Miguel Medina Malone²⁷, Jose Rosas Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrian³⁰, Fred Anton Pages³¹, Jose Ramón Lamua-Riazuelo³², María Dolores Fábregas Canales³³, María José Alados Hernández³⁴, Marta Garijo Bufort³⁵, Anna Pamies³⁶, Luis Sarabia³⁷, Rodrigo Aguirre-del-Pino³⁸, José Ángel Cabezas Lefler³⁹, alvaro seijas³⁸, Carmen Carrasco-Cubero⁴⁰, Ana López-Cerón Cofiño⁴¹, Vera Ortiz-Santamaria⁴², Santos Castañeda⁴³, Maria Laino⁴⁴, Carmen Ordás Calvo⁴⁵, Celia arconada⁴⁶, ana Urruticoechea-Arana⁴⁷, Blanca Garcia-Magallon⁴⁸, Ana Valeria Acosta Alfaro⁴⁹, Samuel Leal Rodriguez⁵⁰, Marina Salido Olivares⁷, Patricia Lavilla Villar⁵¹, Anahy Maria Brandy³, Inmaculada Ros Vilamajo⁵², Alvaro García Martos⁵³, Berta Magallares⁵⁴, Guillen Sada Urmeneta⁵⁵, Cristina Córdoba Martín⁵⁶, Elena Riera Alonso⁵⁷, Carmen Bejerano-Herreria⁵⁸ and Ricardo Blanco,<58, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁰Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain, ¹¹Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ¹³Hospital Central de La Defensa Gómez Ulla, Madrid, Madrid, Spain, ¹⁴Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁵Hospital Universitario Vall D'Hebron, Barcelona, Spain, ¹⁶Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁷Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁹Hospital Provincial de Pontevedra, Pontevedra, Spain, ²⁰Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ²¹Hospital de Mérida, Badajoz, Spain, ²²Hospital Universitario de Torrejón, Madrid, Spain, ²³Hospital General de La Rioja, Logroño, Spain, ²⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁵Hospital Galdakao, Vizcaya, Spain, ²⁶Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ²⁷Hospital de Calahorra, Calahorra, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁹Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁰Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ³¹Hospital General de Segovia, Segovia, Spain, ³²Hospital Universitario del Henares, Madrid, Spain, ³³Hospital de Barbastro, Huesca, Spain, ³⁴Hospital Universitario Puerta del Mar, Cadiz, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital Verge de la Cinta, Tortosa, Tarragona, Spain, ³⁷Complejo Hospitalario de Jaén, Jaén, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Complejo Asistencial de Zamora, Zamora, Spain, ⁴⁰Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴¹Hospital Santa Bárbara, Soria, Spain, ⁴²Hospital General de Granollers, Barcelona, Spain, ⁴³Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁵Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁴⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴⁸Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴⁹Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ⁵⁰Hospital Universitario La Fe, Valencia, Valencia, Spain, ⁵¹Hospital General de Villalba, Collado Villalba, Madrid, Spain, ⁵²Hospital Son Llàtzer, Palma de Mallorca, Spain, ⁵³Hospital del Tajo, Aranjuez, Madrid, Spain, ⁵⁴Hospital de Sant Pau, Barcelona, Spain, ⁵⁵Rheumatology, Hospital Reina Sofía, Tudela, Spain, ⁵⁶Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain, ⁵⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁵⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.

Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…
Abstract Number: 1913 • ACR Convergence 2025
Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
Youngmin Kim¹, Robert Padera², Brittany Weber³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, DEDHAM, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for autoimmune diseases but carries a risk of antimalarial-induced cardiomyopathy (AMIC) that increases with long-term use and is often…
Abstract Number: 1775 • ACR Convergence 2025
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
pradeep sosigowda¹, Phani Kumar D¹, Megha Uppin¹ and Liza rajasekhar², ¹NIMS, Hyderabad, Telangana, India, ²Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases primarily affecting skeletal muscle, with potential involvement of other organs. They are classified…
Abstract Number: 1555 • ACR Convergence 2025
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Alain Lescoat¹, Virginia Steen², Monica Harding³, John VanBuren³, Brian Skaug⁴, Shervin Assassi⁵, Maureen Mayes⁶, Zsuzsanna McMahan⁷, Elana Bernstein⁸, Flavia Castelino⁹, Lorinda Chung¹⁰, Luke Evnin¹¹, Tracy Frech¹², Jessica Gordon¹³, Faye Hant¹⁴, Laura Hummers¹⁵, Kimberly Lakin¹³, Dorota Lebiedz-Odrobina³, Yiming Luo¹⁶, Ashima Makol¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah¹⁵, Ankoor Shah²¹, Elizabeth Volkmann²², Carleigh Zahn²³ and Dinesh Khanna²⁴, ¹CHU Rennes - University Rennes, Rennes, France, ²Georgetown University School of Medicine, Washington, DC, ³University of Utah, Salt Lake City, UT, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷UT Health Houston, Houston, TX, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Stanford, CA, ¹¹Scleroderma Research Foundation, San Francisco, CA, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Columbia University Irving Medical Center, New York, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern University, Chicago, ²⁰University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²¹Duke University, Durham, NC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by a wide range of clinical manifestations and available interventions still lack overall efficacy. Limited cutaneous SSc (lcSSc) and…
Abstract Number: 1918 • ACR Convergence 2025
Vigorous Physical Activity in Patients with SLE Was Not Associated with Disease Activity or Socioeconomic and Social Factors
Heather Gold¹, Yi Li¹, Isabella Giunta¹, Jill Buyon¹, Peter Izmirly², Mala Masson³, Amit Saxena¹, H Michael Belmont⁴, Chung-E Tseng⁵ and Rebecca Anthopolos¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Health, New York, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Flushing, NY
Background/Purpose: Physical activity can mitigate cardiovascular disease and depression risk and improve fatigue, physical function, and quality of life in patients with SLE. To facilitate…
Abstract Number: 1789 • ACR Convergence 2025
Spatial Analysis of Advanced Osteoarthritis Synovial Tissue
jacob Dickman¹, Stephanie Ruzicka¹, Holub Meaghan², Jutras Brandon³, Adam Edelstein³ and Robert Lochhead⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Central Michigan University College of Medicine, Mount Pleasant, MI, ³Northwestern University, Chicago, IL, ⁴Medical College of Wisconsin, GERMANTOWN, WI
Background/Purpose: Osteoarthritis (OA) is a joint pathology involving joint cartilage destruction and synovial inflammation. Severe knee OA is often surgically treated with total knee arthroplasty…
Abstract Number: 0005 • ACR Convergence 2025
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Fengxia Li¹, Jianming Sun¹, Hailin Wang¹, Yan Zhu¹, Xiaoxiao Liu¹, Jing Li¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Min Chen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: 1818 • ACR Convergence 2025
Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
Desire Casares Marfil¹, Gülşah Kavrul Kayaalp², Vafa Guliyeva², Özlem Akgün², Şeyma Türkmen³, Elif Kilic Konte⁴, Seher Şener⁵, Sezgin Sahin⁴, Ozgur Kasapcopur⁶, Betul Sozeri⁷, Selçuk Sözer Tokdemir⁸, Seza Özen⁹, Nuray Aktay Ayaz² and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Istanbul University Faculty of Medicine, Istanbul, Turkey, ³University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Health sciences university, Istanbul, Turkey, ⁸Istanbul University, Istanbul, Turkey, ⁹Hacettepe University Medical Faculty, Ankara, Turkey
Background/Purpose: Childhood-onset lupus is generally associated with a more severe disease course than adult-onset lupus. DNA methylation alterations are known to play a key role…
Abstract Number: 1565 • ACR Convergence 2025
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Zsuzsanna McMahan¹, Swapna Joshi², Jennifer Labus², Arissa Young², Andrea Low³, Vanessa Smith⁴, Susanna Proudman⁵, Antonia Valenzuela⁶, Phoebe Hunter⁷, Kristofer Andréasson⁸, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁹, ¹UT Health Houston, Houston, TX, ²UCLA, Los Angeles, ³Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, ⁴Ghent University Hospital, Gent, Belgium, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ⁹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease…
Abstract Number: 1921 • ACR Convergence 2025
Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
Jiha Lee¹, Jonathan Martindale², Una Makris³ and Julie Bynum², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with rheumatoid arthritis (RA) treated with biologic disease-modifying antirheumatic drugs (bDMARDs), including anti-TNFs, are at an increased risk of adverse effects. Current…
Abstract Number: 1808 • ACR Convergence 2025
Lightsheet imaging with 3D analysis for wholistic assessment of synovial lymphatic vasculature within joints of murine models of arthritis
Xi Lin¹, Edward Schwarz² and Lianping Xing³, ¹University of Rochester, Rochester, NY, ²University of Rochester, Rochester, NY, USA, Rochester, NY, ³University of Rochester, Webster, NY
Background/Purpose: The synovial lymphatic system (SLS) maintains joint homeostasis. Post-traumatic osteoarthritis (PTOA) has increased lymphatic vessels (LVs), but decreased SLS drainage. LVs are routinely studied…
Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 1825 • ACR Convergence 2025
Serum proteomic and single cell RNA sequencing analysis reveals macrophage activation syndrome physiology and widespread complement dysregulation are associated with severe dengue infection in a pediatric cohort
Sarah McCuaig¹, Molly Gallagher¹, Yentli E. Soto Albrecht², Francia Acosta³, Shanti Turbi-Cornielle⁴, Reyna Soriano⁴, Eugenia Gonzalez-Diaz⁴, Vincenta Sanchez⁵, Elsa Herrera⁶, Aide Cornielle⁴, Anabel Fernandez¹, Adriana LaMonte¹, Sarah E Henrickson¹, Laura Vella¹, Andrew P Steenhoff⁷ and Edward Behrens⁸, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Ninos Primeros en Salud Program, Consuelo, Dominican Republic, ⁴Universidad Central del Este, San Pedro de Macorís, Dominican Republic, ⁵Robert Reid Cabral Children's Hospital, Santo Domingo, Dominican Republic, ⁶Dr. Antonio Musa Regional Hospital, San Pedro de Macorís, Dominican Republic, ⁷Children's Hospital of Philadelphia, Philadelphia, ⁸CHOP, West Chester, PA
Background/Purpose: Dengue virus (DENV) is a global public health threat that is increasing in incidence and endogenous DENV infections are expected to dramatically rise in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].